Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia

New England Journal of Medicine

Volumn 331, Issue 14, 1994, Pages 896-903

  Mayer, Robert J ^a   Davis, Roger B ^b   Schiffer, Charles A ^c   Berg, Deborah T ^a   Powell, Bayard L ^d   Schulman, Philip ^e   Omura, George A ^f   Moore, Joseph O ^g   Mcintyre, O Ross ^h   Frei, Emil ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h NORRIS COTTON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; AGING; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYTARABINE; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL RATE;

EID: 0027941369     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199410063311402     Document Type: Article

References (56)

1. Battista R, Bassan R, D'Emilio A, Short-term remission induction and consolidation therapy for adult acute myelogenous leukemia. Hematol Oncol 1991; 9: 43-52
2. Buchner T, Urbanitz D, Hiddemann W, Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985; 3: 1583-1589
3. Cassileth PA, Lynch E, Hines JD, Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79: 1924-1930
4. Harousseau JL, Milpied N, Briere J, Double intensive consolidation chemotherapy in adult acute myeloid leukemia. J Clin Oncol 1991; 9: 1432-1437
5. Mayer RJ, Schiffer CA, Peterson BA, Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Semin Oncol 1987; 14: Suppl 1: 25-31
6. Rees JKH, Gray RG, Swirsky D, Hayhoe FGJ Principal results of the Medical Research Council's 8th Acute Myeloid Leukaemia Trial. Lancet 1986; 2: 1236-1241
7. Schiller G, Gajewski J, Territo M, Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992; 80: 2977-2982
8. Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood 1983; 62: 315-319
9. Bennett JM, Andersen JW, Cassileth PA Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group (ECOG) experience. Leuk Res 1991; 15: 223-227
10. Jacobs P, Dubovsky DW, Wood L In adult acute nonlymphoblastic leukaemia, extended maintenance chemotherapy has no benefit. Am J Hematol 1984; 16: 255-265
11. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Bodey GP, Freireich EJ Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia. Cancer 1986; 58: 1603-1608
12. Passe S, Mike V, Mertelsmann R, Gee TS, Clarkson BD Acute nonlymphoblastic leukemia: prognostic factors in adults with long-term follow-up. Cancer 1982; 50: 1462-1471
13. Peterson BA, Bloomfield CD Long-term disease-free survival in acute nonlymphocytic leukemia. Blood 1981; 57: 1144-1147
14. Sauter C, Berchtold W, Fopp M, Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet 1984; 1: 379-382
15. Schiffer CA, Mayer RJ. Cancer and Leukemia Group B (CALGB): studies in acute myeloid leukemia. In: Gale RP, ed. Acute myelogenous leukemia: progress and controversies. New York: Wiley-Liss, 1990:313-22.
16. Vogler WR, Winton EF, Gordon DS, Raney MR, Go B, Meyer L A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial. Blood 1984; 63: 1039-1045
17. Preisler HD, Raza A, Early A, Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J Clin Oncol 1987; 5: 722-730
18. Tricot G, Boogaerts MA, Vlietinck R, Emonds MP, Verwilghen RL The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia. Br J Haematol 1987; 66: 37-44
19. Wolff SN, Herzig RH, Fay JW, High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol 1989; 7: 1260-1267
20. Curative consolidation chemotherapyLancet 1984; 1: 1389-1390
21. Bloomfield CD Postremission therapy in acute myeloid leukemia. J Clin Oncol 1985; 3: 1570-1572
22. Mayer RJ, Weinstein HJ, Coral FS, Rosenthal DS, Frei E III The role of intensive postinduction chemotherapy in the management of patients with acute myelogenous leukemia. Cancer Treat Rep 1982; 66: 1455-1462
23. Worsley AM, Galton DAG Acute myeloid leukaemia: is consolidation' therapy necessary? Br J Haematol 1984; 56: 361-364
24. Skipper HE, Schabel FM Jr, Wilcox WS Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother Rep 1964; 35: 1-11
25. McCulloch EA, Buick RN, Curtis JE, Messner HA, Senn JS The heritable nature of clonal characteristics in acute myeloblastic leukemia. Blood 1981; 58: 105-109
26. Bennett JM, Catovsky D, Daniel M-T, Proposals for the classification of the acute leukaemias: French-American-British (FAB) Co-operative Group. Br J Haematol 1976; 33: 451-458
27. Bennett JM, Catovsky D, Daniel M-T, Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7): a report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 460-462
28. Bennett JM, Catovsky D, Daniel M-T, Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625
29. Weiss RB, Vogelzang NJ, Peterson BA, A successful system of scientific data audits for clinical trials: a report from the Cancer and Leukemia Group B. JAMA 1993; 270: 459-464
30. Ellison RR, Holland JF, Weil M, Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968; 32: 507-523
31. Rai KR, Holland JF, Glidewell OJ, Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood 1981; 58: 1203-1212
32. Preisler HD Failure of remission induction in acute myelocytic leukemia. Med Pediatr Oncol 1978; 4: 275-276
33. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley, 1981.
34. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
35. Peto R, Pike MC, Armitage P, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39
36. Cox DR Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-220
37. Dick FR, Armitage JO, Burns CP Diagnostic concurrence in the subclassification of adult acute leukemia using French-American-British criteria. Cancer 1982; 49: 916-920
38. Sultan C, Deregnaucourt J, Ko YW, Distribution of 250 cases of acute myeloid leukaemia (AML) according to the FAB classification and response to therapy. Br J Haematol 1981; 47: 545-551
39. Bolwell BJ, Cassileth PA, Gale RP High dose cytarabine: a review. Leukemia 1988; 2: 253-260
40. Mayer RJ Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. Semin Oncol 1987; 14: 384-396
41. Bishop JF, Young GA, Szer J, Matthews JP, Page A Randomized trial of high dose cytosine arabinoside (ara-C) combination in induction in acute myeloid leukemia (AML). Prog Proc Am Soc Clin Oncol 1992; 11: 260-260 abstract.
42. Wieck J, Kopecky K, Appelbaum F, A randomized investigation of high-dose (HDAC) versus standard dose (SDAC) cytosine arabinoside with daunorubicin (DNR) in patients with acute myelogenous leukemia. Prog Proc Am Soc Clin Oncol 1992; 1: 261-261 abstract.
43. Moore JO, Schiffer CA, Amrein PC, G-CSF reduces the duration of both granulocytopenia and thrombocytopenia after AZQ/mitoxantrone consolidation in acute myelogenous leukemia -- CALGB 9022. Blood 1992; 80: Suppl 1: 291a-291a abstract.
44. Baker WJ, Royer GL Jr, Weiss RB Cytarabine and neurologic toxicity. J Clin Oncol 1991; 9: 679-693
45. Rubin EH, Andersen JW, Berg DT, Schiffer CA, Mayer RJ, Stone RM Risk factors for high-dose cytarabine neurotoxicity: an analysis of a Cancer and Leukemia Group B trial in patients with acute myeloid leukemia. J Clin Oncol 1992; 10: 948-953
46. Stone RM, Mayer RJ The approach to the elderly patient with acute myeloid leukemia. Hematol Oncol Clin North Am 1993; 7: 65-79
47. Preisler H, Davis RB, Kirshner J, Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. Blood 1987; 69: 1441-1449
48. Butturini A, Gale RP Chemotherapy versus transplantation in acute leukaemia. Br J Haematol 1989; 72: 1-8
49. Hurd DD Postremission therapy for the younger adult patient with acute myelogenous leukemia: defining a role for transplantation. J Clin Oncol 1993; 11: 1636-1638
50. Mayer RJ Allogeneic transplantation versus intensive chemotherapy in first-remission acute leukemia: is there a “best choice?” J Clin Oncol 1988; 6: 1532-1536
51. Berman E, Little C, Gee T, O'Reilly R, Clarkson B Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation. N Engl J Med 1992; 326: 156-160
52. Young JW, Papadopoulos EB, Cunningham I, T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood 1992; 79: 3380-3387
53. Clift RA, Buckner CD, Appelbaum FR, Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76: 1867-1871
54. Bortin MM, Horowitz MM, Rowlings PA, 1993 Progress report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1993; 12: 97-104
55. Gorin NC, Labopin M, Meloni G, Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. Leukemia 1991; 5: 896-904
56. Schiller GJ, Nimer SD, Territo MC, Ho WG, Champlin RE, Gajewski JL Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J Clin Oncol 1992; 10: 41-46